HIV Viral Rebound Due to a Possible Drug–Drug Interaction between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Calcium-Containing Products: Report of 2 Cases

Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) is a potent fixed-dose, once-daily regimen for HIV-1 treatment and has rare emergence of drug resistance. We report a potential drug–drug interaction in 2 female patients both receiving treatment for HIV and cerebral toxoplasmos...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang-Birken, S. Lena, El-sayed, Dena, Prichard, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748456/
https://www.ncbi.nlm.nih.gov/pubmed/30798679
http://dx.doi.org/10.1177/2325958218821653
_version_ 1783452093905895424
author Kang-Birken, S. Lena
El-sayed, Dena
Prichard, John
author_facet Kang-Birken, S. Lena
El-sayed, Dena
Prichard, John
author_sort Kang-Birken, S. Lena
collection PubMed
description Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) is a potent fixed-dose, once-daily regimen for HIV-1 treatment and has rare emergence of drug resistance. We report a potential drug–drug interaction in 2 female patients both receiving treatment for HIV and cerebral toxoplasmosis: one case between E/C/F/TAF with calcium carbonate and a second case involving leucovorin as calcium salt. Both cases resulted in rise in HIV RNA levels and emergence of M184 V mutation and resistance to elvitegravir and raltegravir. To the best of our knowledge, these 2 cases are the first reports of rapid emergence of mutation from coadministration of E/C/F/TAF and calcium.
format Online
Article
Text
id pubmed-6748456
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-67484562019-11-04 HIV Viral Rebound Due to a Possible Drug–Drug Interaction between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Calcium-Containing Products: Report of 2 Cases Kang-Birken, S. Lena El-sayed, Dena Prichard, John J Int Assoc Provid AIDS Care Case Report Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) is a potent fixed-dose, once-daily regimen for HIV-1 treatment and has rare emergence of drug resistance. We report a potential drug–drug interaction in 2 female patients both receiving treatment for HIV and cerebral toxoplasmosis: one case between E/C/F/TAF with calcium carbonate and a second case involving leucovorin as calcium salt. Both cases resulted in rise in HIV RNA levels and emergence of M184 V mutation and resistance to elvitegravir and raltegravir. To the best of our knowledge, these 2 cases are the first reports of rapid emergence of mutation from coadministration of E/C/F/TAF and calcium. SAGE Publications 2019-01-07 /pmc/articles/PMC6748456/ /pubmed/30798679 http://dx.doi.org/10.1177/2325958218821653 Text en © The Author(s) 2019 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Kang-Birken, S. Lena
El-sayed, Dena
Prichard, John
HIV Viral Rebound Due to a Possible Drug–Drug Interaction between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Calcium-Containing Products: Report of 2 Cases
title HIV Viral Rebound Due to a Possible Drug–Drug Interaction between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Calcium-Containing Products: Report of 2 Cases
title_full HIV Viral Rebound Due to a Possible Drug–Drug Interaction between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Calcium-Containing Products: Report of 2 Cases
title_fullStr HIV Viral Rebound Due to a Possible Drug–Drug Interaction between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Calcium-Containing Products: Report of 2 Cases
title_full_unstemmed HIV Viral Rebound Due to a Possible Drug–Drug Interaction between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Calcium-Containing Products: Report of 2 Cases
title_short HIV Viral Rebound Due to a Possible Drug–Drug Interaction between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Calcium-Containing Products: Report of 2 Cases
title_sort hiv viral rebound due to a possible drug–drug interaction between elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and calcium-containing products: report of 2 cases
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748456/
https://www.ncbi.nlm.nih.gov/pubmed/30798679
http://dx.doi.org/10.1177/2325958218821653
work_keys_str_mv AT kangbirkenslena hivviralreboundduetoapossibledrugdruginteractionbetweenelvitegravircobicistatemtricitabinetenofoviralafenamideandcalciumcontainingproductsreportof2cases
AT elsayeddena hivviralreboundduetoapossibledrugdruginteractionbetweenelvitegravircobicistatemtricitabinetenofoviralafenamideandcalciumcontainingproductsreportof2cases
AT prichardjohn hivviralreboundduetoapossibledrugdruginteractionbetweenelvitegravircobicistatemtricitabinetenofoviralafenamideandcalciumcontainingproductsreportof2cases

Ejemplares similares